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safety evaluation protocols due to the fact that these assays 
tend to generate relatively large numbers of false negative as 
well as false positive read outs (Hartung 2009).
Toxicological dose descriptors
Obviously, to some extent inter-species differences in toxi-
cant susceptibility may account for this lack of predictive 
accuracy of preclinical animal models. This consideration 
has initiated tremendous global efforts in developing alter-
native approaches for evaluating chemical safety such as 
Tox21 in the USA, TG-GATEs in Japan, and, within the 
EU, amongst others, the SEURAT programme, all of which 
use in vitro human cell models for developing accurate and 
non-animal based assays for predicting human organ toxic-
ity risks.
General introduction
For more than a decade pharmaceutical R&D has been 
hampered by considerable attrition rates during clinical tri-
als. The main reasons for drug failure is related to the lack 
of efficacy, limitations with respect to ADME (absorption, 
distribution, metabolism and excretion) properties, and—in 
approximately 30% of the cases—unforeseen toxicity (Kola 
and Landis 2004). The majority of adverse drug reactions 
observed in the clinical phase refer to organ injuries, e.g. 
of the cardiovascular system, the liver, the central nervous 
system and skeletal muscle (Cook et al. 2014). This clearly 
demonstrates the limited predictive accuracy of current pre-
clinical models such as the rodent bioassay in evaluating 
repeated dose toxicity for predicting human toxic risks. It 
has been argued that overall, only 43% of toxic effects in 
humans may be correctly predicted by applying rodent-based 
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A second argument for explaining the observed lack of 
predictive capacity of animal toxicity models is attributable 
to the application of fairly high doses of the compound in 
rodent studies (the OECD Test Guideline for the 28 days 
repeated dose toxicity study requires a highest dose level 
which should induce toxic effects but not yet death or severe 
suffering) which are unlikely to be reached in patients during 
clinical trials of new drug candidates, or, upon market intro-
duction, in drug-treated patients. Moreover, it has been criti-
cized that in general, in vitro models for assessing toxicity 
also tend to apply relatively high incubation concentrations 
of test compounds which do not reflect blood levels achieved 
in experimental animals, or in patients, for assessing tox-
icity (Wambaugh et al. 2015). In order to cope with this 
discrepancy, currently ongoing EU research programmes, 
e.g. HeCaToS and EUToxRisk, aim to apply physiologically 
relevant toxicant doses in vitro calculated from—preferably 
human—kinetic data of the compounds under investigation.
There are already numerous toxicological dose descrip-
tors such as the maximum plasma concentration  (Cmax), the 
average concentration across time  (Caverage) or the area (inte-
gral) under the concentration–time curve (AUC) (Muller and 
Milton 2012) which all compare drug exposure to the inten-
sity of specific adverse events. The establishment of such 
concentration–response correlations requires the systematic 
application of escalation studies to characterize the dose-
dependent effect of a toxicant. However, toxicological dose 
descriptors inevitably reflect an underlying experimental 
setup, for example the drug concentration in the incubation 
media or the duration of drug exposure in an in vitro assay. 
In this regard, it should also be noted that toxicological dose 
descriptors usually quantify pharmacokinetic (PK) drug 
exposure in the venous plasma which is the routine sampling 
site in clinical practice. However, these plasma concentra-
tions are only surrogate markers for the actual tissue level 
where the adverse event ultimately occurs. Depending on the 
physicochemistry or the biological properties of a particular 
drug such tissue levels may differ significantly in different 
organs. Alternatively, physiologically based pharmacoki-
netic (PBPK) models provide a possibility to describe the 
physiology of the body at a large level of detail. Different 
organs are explicitly represented in PBPK models to account 
for their specific physiological role in drug ADME (Kuepfer 
et al. 2016). The organs are further subdivided into the intra-
cellular and the interstitial space as well as into blood plasma 
and red blood cells, respectively. Mass transfer inbetween 
the different sub-compartments is estimated from physico-
chemical properties of the drug such as the lipophilicity or 
the molecular weight. The simulation of drug concentration 
profiles in specific organ compartments allows predicting the 
concentration profile in the extracellular environment which 
corresponds to either the interstitial space of an organ or the 
incubation media of an assay (Hamon et al. 2015). Notably, 
in vitro–in vivo correlations are directly possible through 
this equivalence of drug exposure in the assay and the PBPK 
model, respectively. Likewise, in vitro dose descriptors may 
be directly translated to an in vivo situation to allow for the 
application of pharmacokinetics/pharmacodynamics (PK/
PD) concepts (Derendorf and Meibohm 1999). The con-
cept of model-based assay design developed in HeCaToS 
(Hepatic and Cardiac Toxicity Systems modelling) will be 
introduced in the following.
Model‑based assay design
In an initial step, PBPK models are established for sets of dif-
ferent hepato- and cardio-toxicants and are validated based 
on literature PK data (Fig. 1). Both a therapeutic and a toxic 
drug dose are then simulated for multiple administrations of 
up to two weeks of treatment. The therapeutic dose, repre-
senting the ‘no adverse effect level’, is selected according to 
the drug label. The toxic dose in turn is based upon specific 
in vitro toxicity markers (e.g. IC20). Within HeCaToS, 3D 
liver and heart microtissues are used to account for different 
organ specific manifestations of drug-induced injuries such 
as cardiomyopathy, mitochondrial dysfunction or cholestasis 
(Beauchamp et al. 2015; Proctor et al. 2017). The drug-spe-
cific PBPK models are used to simulate concentration–time 
curves in the interstitial compartment of the liver or the heart. 
The profiles are then discretized at multiple sampling times 
according to a pre-defined, PK-driven experimental sched-
ule. This allows us to approximate the simulated PK profile 
through physiologically relevant incubation concentrations 
which in turn requires replacement of the drug-containing 
assay medium after 2 h, 8 h and 24 h each day. Although this 
is a labour-intensive approach, the concept allows the unbi-
ased analysis of the emergence of drug-induced side effects 
as a function of both time and dose without the prior selection 
of a specific toxicity descriptor. Moreover, the in vitro assay 
mimics the dynamics of actual PK profiles (including tissue 
accumulations of drugs following repeated dosing) and thus 
the tissue exposure in a real patient through the preparatory 
PBPK simulations. Such highly specific tissue concentrations 
cannot be analyzed in vivo since this would require invasive 
sampling. At each time point, 3D microtissues are harvested 
and cross-omics analyses are subsequently performed to track 
the emergence of toxic effects at different levels of cellular 
regulation. This includes epigenomics, transcriptomics, pro-
teomics and metabolomics measurements, as such represent-
ing drug-induced physiological endpoints which are further 
used to characterize induction of toxicity-related pathways 
and to populate different computational models. In this regard, 
comparison of ‘omics data from 3D liver and heart microtis-
sues challenged with either the therapeutic or the toxic dose 
allow the identification of drug-induced pathway responses in 
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a time- as well as a dose-dependent manner. To validate the 
in vitro findings the ‘omics data generated are matched with 
‘omics and clinical data from heart of liver biopsies taken from 
patients treated with the same drugs and showing symptoms of 
target organ toxicity as well as clinical data. The comparison 
of the cross-omics data from the PBPK-based 3D microtissue 
assay with analogous in vivo data from actual patient biopsies 
will allow a rigorous assessment whether patterns of acute 
drug-induced toxicity in patients can actually be reproduced 
in the lab.
In summary, the HeCaToS project aims to establish bet-
ter prediction models for human heart and liver toxicity, by 
challenging 3D human cardiac and hepatic cell models with 
physiologically relevant doses of cardio- and hepatotoxicants 
mimicking in vivo PK profiles. The comprehensive analysis 
of multi-scale deregulation of cell function through cross-
omics approaches compared with molecular data from heart 
or liver biopsies from patients treated with the same toxicants 
for model validation can be expected to significantly enhance 
the relevance and predictivity of in vitro preclinical assays in 
the near future.
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